SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ulta Beauty, Inc. engages in the retail of beauty products. The company has one reportable segment, which includes retail stores, salon services, and e-commerce. Its products include makeup, skin care, tools and brushes, fragrance, and bath and body. The company was founded on January 9, 1990 and is headquartered in Bolingbrook, IL.

Ulta Beauty Inc

Ulta Beauty is experiencing significant market volatility as investors weigh strong quarterly earnings and raised full-year guidance against concerns over broader consumer spending trends. The stock remains a focal point for the trading community, drawing intense debate between those betting on long-term growth and those positioning for short-term pullbacks amid macro headwinds.

Workday, Inc. engages in the provision of development of enterprise cloud applications for finance and human resources. It delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday is trending as investors debate the impact of AI on enterprise software, with the stock recently hitting 52-week lows amid broader volatility in the SaaS sector. While some community members worry that AI disruption threatens traditional subscription models, others argue that Workday's deeply embedded institutional role and resilience in HR spending make current price levels an attractive buying opportunity.

Audiera (BEAT) pioneers the agent-native participation economy, where humans and autonomous AI agents act as equal economic participants. For the first time, Audiera introduces structured agent roles and participation rules — enabling agents to perform tasks, interact with users, create music, compete in rhythm battles, and engage directly in on-chain economic activity. No more treating agents as tools: they hold wallets, earn, spend, and settle value natively. Powered by $BEAT on BNB Chain — fueling incentives, coordination, governance, and shared prosperity in the machine-native future.

BEAT Token

The BEAT token is experiencing heightened social media chatter and volatile price swings as market participants speculate on its potential for exponential growth compared to other meme coins. While some investors are accumulating the asset in anticipation of a significant breakout, others warn of extreme speculative risks, including pump-and-dump concerns and potential confusion with similarly named assets.

Hyatt Hotels Corp. engages in the development and management of resort and hotel chains. It operates through the following segments: Management and Franchising, Owned and Leased, and Distribution. The Management and Franchising segment provides management, franchising, and hotel services, or the licensing of intellectual property to businesses. The Owned and Leased segment is involved with owned and leased hotel properties located predominantly in the United States but also in certain international locations. The Distribution segment refers to the distribution and destination management services offered through ALG Vacations, and the boutique and luxury global travel platform offered through Mr. & Mrs. Smith. The company was founded by Jay Pritzker in 1957 and is headquartered in Chicago, IL.

Hyatt Hotels Corporation - Ordinary Shares - Class A

Hyatt Hotels Corp

Hyatt Hotels Corp is currently drawing investor attention as it navigates a leadership transition following the immediate resignation of Thomas Pritzker as Executive Chairman. While the community is actively debating the reputational impact of his prior associations, the company continues to execute its asset-light growth strategy amidst ongoing sector-wide trends in the luxury travel market.

MNTN, Inc. engages in bringing performance marketing to television, ushering in a new generation of advertisers to Connected TV (CTV). The software company’s self-serve advertising platform and AI-driven precision targeting enable brands of all sizes to achieve measurable results. The company was founded by Mark Douglas in 2009 and is headquartered in Austin, TX.

MNTN Inc. - Ordinary Shares - Class A

MNTN, Inc.

MNTN is trending following the launch of its AI-driven creative platform, an update that has sparked community interest in how its workflow automation and creative tools could serve as a competitive moat. Investors are also actively debating the stock's recent performance and long-term potential, frequently comparing its ad-tech model to industry peers like The Trade Desk.

Sibanye Stillwater Ltd. is a multinational mining and metals processing group with a diverse portfolio of operations, projects and investments across five continents. It is one of the global recyclers of PGM autocatalysts and has interests in mine tailings retreatment operations. The firm mainly engages in the acquisition and exploration of platinum group materials including palladium, rhodium and producing of gold. It also produces and refines iridium, ruthenium, nickel, chrome, copper and cobalt. The company has diversified its asset portfolio into battery metals mining and processing. Sibanye Stillwater was founded on February 1, 2013 and is headquartered in Weltevreden Park, South Africa.

Sibanye Stillwater Limited - ADR

Sibanye Gold Limited

Sibanye Stillwater is trending as investors monitor high buy volume and accumulation in the mining sector, with the community closely tracking potential price appreciation in platinum and palladium as critical supply deficits persist. Market participants are actively discussing the stock's significant recovery potential from multi-year lows, driven by its diverse precious metals portfolio and leverage to stabilizing commodity prices.

Investment Managers Series Trust II - Tradr 2X Long IREN Daily ETF

Tradr 2X Long IREN Daily ETF

IREX is trending as traders closely watch the volatile price action of the underlying stock IREN, with many debating the risks of holding a 2X leveraged ETF during periods of significant market fluctuation. Investors are actively discussing whether to use the vehicle for short-term directional plays on data center and crypto-related sector momentum or to exercise extreme caution to avoid the impacts of daily volatility decay.

American Express Co. engages in the provision of card-issuing, merchant-acquiring, and card network businesses. Its products and services include credit cards, business credit cards, corporate programs, gift cards, savings accounts and CDs, and the American Express App. It operates through the following segments: the United States Consumer Services (USCS), Commercial Services (CS), International Card Services (ICS), Global Merchant and Network Services (GMNS), and Corporate and Other. The USCS segment includes proprietary consumer cards and provides services to United States consumers. The CS segment offers corporate and small business cards and provides services to United States businesses. The ICS segment provides consumers, small businesses, and corporate cards outside the United States. The GMNS segment is involved in operating a global payments network that processes and settles card transactions, acquires merchants, and provides multi-channel marketing programs and capabilities, services and data analytics. The Corporate and Other segment covers corporate functions and certain other businesses and operations. It also operates through the following geographical segments: United States, EMEA, APAC, LACC, and Other. The EMEA segment represents Europe, the Middle East, and Africa. The APAC segment refers to Asia Pacific, Australia, and New Zealand. The LACC segment focuses on Latin America, Canada, and the Caribbean. The Other segment includes net costs which are not directly allocated to specific geographic regions. The company was founded by Henry Wells, William G. Fargo, and John Warren Butterfield on March 28, 1850 and is headquartered in New York, NY.

American Express Co.

American Express (AXP) is trending as investors digest a strong earnings report that showcased robust premium consumer spending and revenue growth, prompting multiple analyst price target hikes. While the community is actively debating the sustainability of this rally against broader macroeconomic risks and valuation concerns, many participants are focused on the stock's role as a resilient, long-term portfolio staple.

Hewlett Packard Enterprise Co. is a global edge-to-cloud company, which engages in the provision of information technology, technology and enterprise products, solutions, and services. It operates through the following segments: Server, Hybrid Cloud, Intelligent Edge, Financial Services, and Corporate Investments and Other. The Server segment consists of general-purpose servers for multi-workload computing and workload-optimized servers to deliver the performance and value for demanding applications, and integrated systems comprised of software and hardware designed to address high-performance computing and supercomputing, artificial intelligence, data analytics, and transaction processing workloads for government and commercial customers globally. The Hybrid Cloud segment is involved in a variety of cloud-native and hybrid solutions across storage, private cloud, and the infrastructure software-as-a-service space. The Intelligent Edge segment offers wired and wireless local area networks, campus, branch, and data center switching, software-defined wide-area-networks, private and public cellular network software, network security, and associated services that enable secure connectivity for businesses of any size. The Financial Services segment provides investment solutions, such as leasing, financing, IT consumption, utility programs, and asset management services for customers that facilitate technology deployment models and the acquisition of complete IT solutions, including hardware, software, and services from Hewlett Packard Enterprise and others. The Corporate Investments and Other segment includes the Advisory and Professional Services business, which primarily offers consultative-led services, HPE and partner technology expertise and advice, implementation services, as well as complex solution engagement capabilities, the Communications and Media Solutions business, which primarily offers software and related services to the telecommunications industry, and Hewlett Packard Labs, which is responsible for research and development. The company was founded by William R. Hewlett and David Packard on July 2, 1939 and is headquartered in Spring, TX.

Hewlett Packard Enterprise Co

Hewlett Packard Enterprise is trending as the community debates its position within the competitive AI infrastructure sector, specifically comparing its server and networking offerings against rivals like Super Micro Computer and Dell. Investors are closely monitoring its strategic pivot toward high-margin networking following the Juniper Networks acquisition, while activist involvement and a fresh $931 million government contract have fueled recent market enthusiasm.

Sun Communities, Inc. provides real estate management services. The firm operates through the following segments: Manufactured Home Communities, Recreational Vehicle, and Marina. The Manufactured Home Communities segment owns, operates, and develops manufactured housing communities and is in the business of acquiring, operating, and developing ground up communities to provide housing solutions. The Recreational Vehicle segment focuses on the development of recreational vehicle resorts and is in the business of acquiring, operating and developing ground up resorts throughout the U.S. and in Ontario, Canada. The Marina segment operates marinas and is in the business of acquiring and operating marinas throughout the U.S. The company was founded in 1975 and is headquartered in Southfield, MI.

Sun Communities, Inc.

Sun Communities is seeing heightened market attention driven by a combination of strong earnings performance and specific investor interest in its financial positioning. The community is actively discussing the stock's stability as a REIT, alongside confusion with a crypto asset of the same ticker, creating a mix of serious financial analysis and speculative sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>REGENXBIO, however, noted that the U.S. Food and Drug Administration recommended a randomized controlled trial for the drug in recent discussions, raising cash concerns.</li><li>Cash, cash equivalents, and marketable securities stood at $150.5 million at Q1-end, which the firm expects to be sufficient to fund its operations into early 2027.</li><li>Both Q1 revenue and earnings fell short of Wall Street expectations on Thursday.</li></ul>Shares of REGENXBIO Inc. (RGNX) dropped 37% on Thursday after the company reported disappointing first-quarter 2026 (Q1) financial results that overshadowed positive pivotal late-stage trial data for its lead Duchenne muscular dystrophy candidate RGX-202.The stock is on track for its worst day ever, if losses hold.<h2 class="st-heading-2">RGNX’s Q1 Earnings</h2>The company reported that revenue for the three months ended March 31 plunged to $6.4 million from $89.0 million a year earlier, and below an analyst estimate of $25.25 million. The steep decline was driven by the absence of a $70 million upfront license payment recognized in Q1 2025 under the Nippon Shinyaku collaboration and lower royalties from Novartis’ ZOLGENSMA after U.S. patent expiration in January 2026.REGENXBIO swung to a net loss of $90.1 million, or $1.72 per share, compared with net income of $6.1 million, or $0.12 per share, in the prior-year quarter. Wall Street, on average, had estimated a loss of only $1.3/ share.Cash, cash equivalents, and marketable securities stood at $150.5 million at quarter-end, which the firm expects to be sufficient to fund its operations into early 2027.<h2 class="st-heading-2">DMD Trial Readout</h2>In a separate announcement, REGENXBIO reported strong results from its main late-stage trial of RGX-202 for Duchenne muscular dystrophy. Duchenne muscular dystrophy (DMD) is a severe, progressive genetic disorder characterized by muscle degeneration and weakness, primarily affecting young boys.The study met its main goal. Ninety-three percent of patients produced high levels of the needed muscle protein after 12 weeks, averaging 71%.One-year data from some patients showed meaningful improvements in movement and muscle function compared to untreated boys. The treatment was generally safe, with two serious side effects that resolved, Regenxbio said.The results support plans for an accelerated approval filing and subsequent launch in 2027, the firm said. REGENXBIO, however, noted that the U.S. Food and Drug Administration recommended a randomized controlled trial for the drug in recent discussions, which could add uncertainty to the timeline, though the company remains optimistic and plans further FDA discussions.<h2 class="st-heading-2"> How Did RGNX Retail Traders React?</h2>On Stocktwits, retail sentiment around RGNX stock increased from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.A Stocktwits user expressed hopes for the stock recovering after the “overreaction.” The user sees the company’s market cap touching $1 billion in time, up from its current near $330 million market cap now.<stembedurl>https://www.stocktwits.com/buymoremakemore/message/653352403</stembedurl>Another user expressed hopes for Novartis buying the company.<stembedurl>https://www.stocktwits.com/murphylaw/message/653377645</stembedurl>Another user highlighted that the company doesn’t seem to have enough cash to conduct another trial if the FDA insists.<stembedurl>https://www.stocktwits.com/Find_the_Cure/message/653359896</stembedurl><a href="https://stocktwits.com/symbol/RGNX">RGNX stock</a> has fallen by about 23% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ivvd-stock-fell-today-but-this-analyst-sees-730-percent-upside/cZX1UFNReSa">IVVD Stock Tanks 19% Today – But This Analyst Believes It Has A Potential Upside Of Over 730%</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Regenxbio logo is displayed on the screen of a smart tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

RGNX Stock On Track For Worst Day Ever As Big Q1 Loss, Cash Concerns Eclipse Duchenne Trial Success  

REGENXBIO on Thursday reported strong results from its main late-stage trial of RGX-202 for Duchenne muscular dystrophy.

Equity

REGENXBIO on Thursday reported strong results from its main late-stage trial of RGX-202 for Duchenne muscular dystrophy.


REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval

REGENXBIO reports positive Phase 3 Duchenne trial data as RGX-202 met its primary endpoint with strong safety results.read more...

Regenxbio Shares Rise After Positive Duchenne Trial Results

Regenxbio Shares Rise After Positive Duchenne Trial Results...

Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates

Regenxbio (RGNX) delivered earnings and revenue surprises of -26.94% and -73.13%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights

REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights PR Newswire ROCKVILLE, Md., May 14...

REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE Study of RGX-202

REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE Study of RGX-202 REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE Study of...

<ul class="summary-bullets"><li>The plans come on the heels of several complaints from the pharmaceutical industry and sparring with others in the health department over policy, the report added.</li><li>Makary, a former Johns Hopkins surgeon, joined the FDA in November 2024.</li><li>Shares of REPL and QURE jumped as much 17% following the report.</li></ul>President Donald Trump is reportedly considering firing U.S. Food and Drug Administration Commissioner Marty Makary.The Wall Street Journal <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/healthcare/trump-planning-to-fire-fda-commissioner-marty-makary-34c072e2">reported</a> on the plans on Friday, citing people familiar with the matter, while noting that other top administration officials believe Makary is struggling to manage his agency. The plans come on the heels of several complaints from the pharmaceutical industry and sparring with others in the health department over policy, the report added.However, the president’s plans are not final and could change, the report said. WSJ noted that Makary, if fired, would become the latest top lieutenant to be fired under Health and Human Services Secretary Robert F. Kennedy Jr., following the departures of CDC Director Susan Monarez last summer and HHS Deputy Secretary Jim O’Neill in February.Makary, a former Johns Hopkins surgeon, joined the FDA in November 2024.<h2 class="st-heading-2">Companies Likely To Benefit from Makary’s Exit</h2>Several biotech and pharmaceutical firms that have publicly clashed with the Makary-led FDA over what they describe as inconsistent, unpredictable, or overly restrictive drug-review processes are viewed as potential beneficiaries of new leadership that could accelerate approvals and restore clearer regulatory guidance.Replimune Group Inc. (<a href="https://stocktwits.com/symbol/REPL">REPL</a>): The FDA rejected the company’s lead melanoma therapy RP1 in a high-profile decision that drew intense industry backlash. Replimune argued the agency treated it unfairly and failed to honor prior commitments made during review meetings; the case became a flashpoint in broader criticism of Makary’s tenure.uniQure N.V. (<a href="https://stocktwits.com/symbol/QURE">QURE</a>): The agency issued a sudden “key shift” in feedback on the company’s Huntington’s disease gene therapy AMT-130, reversing earlier assurances about the sufficiency of its Phase 1/2 data. The FDA strongly recommended a new, randomized, double-blind, sham-surgery-controlled trial.Moderna Inc. (<a href="https://stocktwits.com/symbol/MRNA">MRNA</a>): CEO Stéphane Bancel publicly stated that the FDA under Makary had become “unpredictable” in a way that “threatens U.S. leadership in innovative medicines.” The company experienced surprise setbacks, including an initial refusal to accept a flu vaccine application that was later reversed.Regenxbio Inc. (<a href="https://stocktwits.com/symbol/RGNX">RGNX</a>): The FDA declined to approve the company’s gene therapy for the ultra-rare Hunter syndrome (MPS II) in February 2026, despite prior engagement. Industry observers cited this as part of a pattern of moving goalposts that has frustrated rare-disease developers.Sarepta Therapeutics Inc. (<a href="https://stocktwits.com/symbol/SRPT">SRPT</a>): Sarepta faced repeated conflicts over its Duchenne muscular dystrophy gene therapy Elevidys, including safety and efficacy disputes under Makary’s oversight and the influence of former FDA official Vinay Prasad.Other biotech stocks likely to benefit from under new FDA leadership include Hims &amp; Hers Health (<a href="https://stocktwits.com/symbol/HIMS">HIMS</a>), which faced direct public criticism from Makary over its compounded GLP-1 weight-loss products, and rare-disease gene- and RNA-therapy developers such as Dyne Therapeutics (<a href="https://stocktwits.com/symbol/DYN">DYN</a>), Avidity Biosciences (<a href="https://stocktwits.com/symbol/RNA">RNA</a>), and Lexeo Therapeutics (<a href="https://stocktwits.com/symbol/LXEO">LXEO</a>), all of which have cited inconsistent feedback and delays during Makary’s tenure.Shares of REPL jumped 17% at the time of writing, while QURE rose 15%. MRNA traded 10% higher, while SRPT stock traded 3% lower, and RGNX shares stayed flat.<h2 class="st-heading-2">How Did Retail Traders React?</h2>A Stocktwits user voiced optimism for eventual approval of Replimune’s RP-1 drug, calling the decision to deny it approval a “terrible one.”<stembedurl>https://www.stocktwits.com/History101/message/652782029</stembedurl>Another voiced optimism for “someone better” replacing Makary.<stembedurl>https://www.stocktwits.com/blueb22/message/652773597</stembedurl>While REPL shares fell by about 50% over the past 12 months, QURE rose 124%.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/lucid-uber-partnership-accelerates-after-nuro-lands-key-california-permit-for-gravity-robotaxis/cZX2AwwReg1">LCID-UBER Partnership Accelerates After Nuro Lands Key California Permit for Gravity Robotaxis</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

FDA Commissioner Marty Makary speaks at a news conference on removing synthetic dyes from America's food supply, at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. (Photo by Nathan Posner/Anadolu via Getty Images)

REPL, QURE, MRNA Soar On Reports Trump Will Fire FDA’s Marty Makary 

The Wall Street Journal reported on the plans on Friday, citing people familiar with the matter, while noting that other top administration officials believe Makary is struggling to manage his agency.

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual...

EyePoint (EYPT) Reports Q1 Loss, Tops Revenue Estimates

EyePoint (EYPT) delivered earnings and revenue surprises of -25.32% and +132.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy

REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from...

$RGNX Q1 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$1.72 down -1533.33% YoY
• Reported revenue of $6.39M down -92.82% YoY
• Regenxbio expects its balance in cash, cash equivalents, and marketable securities of $150.5M as of March 31, 2026, to fund its operations into early 2027.

Stocktwits

 Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of -$1.72 down -1533.33% YoY
• Reported revenue of $6.39M down -92.82% YoY
• Regenxbio expects its balance in cash, cash equivalents, and marketable securities of $150.5M as of March 31, 2026, to fund its operations into early 2027.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Current Price	$5.72
Prev Close	$6.25
Open	$6.25
Dividend Yield	0.00%
50-Day Moving Average	$8.88
Beta	1.63
Avg. Volume	558,611.81
PE Ratio	-1.02

52-Week High	$16.19
52-Week Low	$5.71
Market Capitalization	$322.35M
EPS (Annual)	-$3.76
Price to Book	14.00
Revenue Per Employee	$459,409.70

RGNX
Regenxbio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RGNX News

RGNXRegenxbio Inc